Treatment strategies targeting the immune system provide the opportunity for antitumor activity across multiple cancer types regardless of mutational status or tumor histology. While many of the initial advances in immunotherapy have been in melanoma, the focus has now broadened to include many other solid as well as hematological cancers. Different immunotherapeutic approaches are being evaluated across tumor types and their various novel mechanisms of action and safety profiles offer the potential for a variety of combination regimens. Ongoing and planned investigation of these immunotherapies, alone and in combination, represents the start of a new chapter in our treatment of cancer and offers the hope of better outcomes for patients with a wide range of cancers. Recently, advances have been made in the use of immune-based approaches to treat other cancer types, such as non-small-cell lung cancer, breast cancer, ovarian cancer, gastrointestinal cancer, hepatocellular carcinoma, head and neck cancer, and lymphoma. We invite investigators to submit original research articles and reviews to this special issue.

Potential topics include but are not limited to the following:

• Tumor and host factors controlling antitumor immunity and immunotherapy efficacy
• Identification of prognostic and predictive biomarkers
• Combinations of checkpoint inhibitors
• Beyond PD-1/PD-L1 axis blockade: combinations or new molecules
• Finding the best combination in immunotherapy: a paradigm shift in cancer therapy
• Stimulation of anticancer immunity by new mechanisms and combinations
• Antibody based immunotherapy
• Adoptive T cell therapy
• Different aspects of the interaction between cancer and the immune system
• Immunooncology clinical studies across different tumor types